Alnylam Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Alnylam is leading the translation of RNA interference into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system. Alnylam’s commercial RNAi therapeutic products are ONPATTRO, approved in the U.S., EU, Canada, Japan, Brazil, and Switzerland, and GIVLAARI, approved in the U.S and the EU.
Alnylam Pharmaceuticals stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Alnylam Pharmaceuticals balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Alnylam Pharmaceuticals cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Alnylam Pharmaceuticals multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Alnylam Pharmaceuticals profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Alnylam Pharmaceuticals assets
Alnylam Pharmaceuticals cash flows

Alnylam Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
ALNY:USAlnylam Pharmaceuticals, Inc.Common share-US02043Q1076$146.5
Alnylam Pharmaceuticals news
28.04.2022
Alnylam Pharmaceuticals' GAAP loss for 3 months of 2022 was $240.341 million, up 20% from $200.291 million in the previous year. Revenue increased 20.1% to $213.259 million from $177.566 million a year earlier.
Source: {source} pictogram investors.alnylam.com
Pictogram next
10.02.2022
Alnylam Pharmaceuticals' GAAP loss for 2021 was $852.824 million, down 0.6% from $858.281 million in the previous year. Revenue increased 71.3% to $844.287 million from $492.853 million a year earlier.
Source: {source} pictogram investors.alnylam.com
Pictogram next
28.10.2021
Alnylam Pharmaceuticals' GAAP loss for 9M 2021 was $594.364 million, down 3.3% from $614.741 million in the previous year. Revenue increased 77.9% to $585.752 million from $329.291 million a year earlier.
Source: {source} pictogram investors.alnylam.com
Pictogram next
03.08.2021
Alnylam Pharmaceuticals' GAAP loss for 6 months of 2021 was $389.85 million, up 7.9% from $361.45 million in the previous year. Revenue increased 95.7% to $398.119 million from $203.438 million a year earlier.
Source: {source} pictogram investors.alnylam.com
Pictogram next
All Alnylam Pharmaceuticals news
General information
Company nameAlnylam Pharmaceuticals
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address300 THIRD STREET CAMBRIDGE MA 02142 (617) 551-8200
Mailing address300 THIRD STREET CAMBRIDGE MA 02142
Websitewww.alnylam.com
Information disclosurewww.sec.gov